Letter to the editor: Pitfalls in the outcome differences between NAFLD and MAFLD
Dina Attia, Ahmed Gomaa, Shereen Abdel Alem – 8 May 2022
Reply to the Letter to the editor “Ipragliflozin improves the hepatic outcomes of patients with diabetes with NAFLD”
Hirokazu Takahashi, Keizo Anzai – 8 May 2022
Nonalcoholic fatty liver disease prevalence and severity in Asian Americans from the national health and nutrition examination surveys 2017–2018
Emily Truong, Yee Hui Yeo, Galen Cook‐Wiens, Mark Muthiah, Ju Dong Yang, Vinay Sundaram, Devon Chang, Tsuyoshi Todo, Irene K. Kim, Shelly C. Lu, Veronica Wendy Setiawan, Vincent W. S. Wong, Stephen A. Harrison, Naim Alkhouri, Mazen Noureddin – 8 May 2022 – Studies have examined nonalcoholic fatty liver disease (NAFLD) prevalence and severity in Asians; however, this is not well understood in Asian Americans (both East and South Asian Americans) as few studies have analyzed this population.
Reply
Cyriac Abby Philips, Ajay Kumar Patwa, Pavan Hanchanale, Chetan Kalal, Saptarshi Bishnu, Mithun Sharma, the Liver Research Club India (LIVERECI) – 8 May 2022
CAQ Corner: Evolution of liver allocation policy
Ammar Hassan, Pratima Sharma – 8 May 2022
CAQ Corner: Evolution of liver allocation policy
Ammar Hassan, Pratima Sharma – 8 May 2022
Simple bedside tests as an alternative to sarcopenia HIBA score in predicting sarcopenia and mortality in cirrhosis
Surender Singh, Nikhil Bush, Sunil Taneja – 8 May 2022
Letter to the editor: Apples should be compared with apples
Yasser Fouad, Waleed A. Abdel Dayem, May Mehrez – 8 May 2022
Abnormal liver tests are not sufficient for diagnosis of hepatic graft‐versus‐host disease in critically ill patients
Alexander H. Yang, Mai Ai Thanda Han, Niharika Samala, Bisharah S. Rizvi, Rachel Marchalik, Ohad Etzion, Elizabeth C. Wright, Ruchi Patel, Vinshi Khan, Devika Kapuria, Vikramaditya Samala Venkat, David E. Kleiner, Christopher Koh, Jennifer A. Kanakry, Christopher G. Kanakry, Steven Pavletic, Kirsten M. Williams, Theo Heller – 8 May 2022 – Hepatic graft‐versus‐host disease (HGVHD) contributes significantly to morbidity and mortality after hematopoietic stem cell transplantation (HSCT). Clinical findings and liver biomarkers are neither sensitive nor specific.